Procollagen type III amino‐terminal propeptide and insulin‐like growth factor I as biomarkers of growth hormone administration
Open Access
- 21 August 2021
- journal article
- review article
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (5) , 808-819
Abstract
The acceptance in 2012 by the World Anti‐Doping Agency (WADA) of the biomarker test for human growth hormone (hGH) based on procollagen type III amino‐terminal propeptide (P‐III‐NP) and insulin‐like growth factor I (IGF‐I) was perhaps the first time that such a method has been used for forensic purposes. Developing a biomarker test to anti‐doping standards, where the strict liability principle applies, is discussed. An alternative WADA‐accepted approach is based on the measurement of different hGH isoforms, a method that suffers from the very short half‐life of hGH limiting the detection period. Modification or withdrawal of the immunoassays, on which the biomarker measurements largely depend, has necessitated revalidation of the assays, remeasurement of samples and adjustment of the decision limits above which an athlete will be assumed to have administered hGH. When a liquid chromatography coupled mass spectrometry (LC–MS) method became a reality for the measurement of IGF‐I, more consistency of results was assured. Measurement of P‐III‐NP is still dependent on immunoassays although work is underway to develop an LC–MS method. The promised long‐term detection time for the biomarker assay does not appear to have been realised in practice, and this is perhaps partly the result of decision limits being set too high. Nevertheless, more robust assays are needed before a further adjustment of the decision limit is warranted. In the meantime, WADA is considering using P‐III‐NP and IGF‐I as components of a biomarker passport system recording data from an individual athlete, rather than the population. Using this approach, smaller perturbations in the growth hormone (GH) score would mandate an investigation and possible action for hGH administration.Keywords
Funding Information
- Partnership for Clean Competition
This publication has 84 references indexed in Scilit:
- Clinical Utility of Insulin-Like Growth Factor 1 and 2; Determination by High Resolution Mass SpectrometryPLOS ONE, 2012
- Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathwaysNature Genetics, 2012
- What are biomarkers?Current Opinion in HIV and AIDS, 2010
- Prolyl 4-hydroxylaseCritical Reviews in Biochemistry and Molecular Biology, 2010
- The Direct Binding of Insulin-like Growth Factor-1 (IGF-1) to Integrin αvβ3 Is Involved in IGF-1 SignalingJournal of Biological Chemistry, 2009
- High‐throughput ultra‐high‐performance liquid chromatography/tandem mass spectrometry quantitation of insulin‐like growth factor‐I and leucine‐rich α‐2‐glycoprotein in serum as biomarkers of recombinant human growth hormone administrationRapid Communications in Mass Spectrometry, 2009
- Challenges in Detecting the Abuse of Growth Hormone in SportClinical Chemistry, 2005
- Ehlers‐Danlos syndrome and type III collagen abnormalities: a variable clinicalClinical Genetics, 1998
- Evidence that somatomedin is synthesized by multiple tissues in the fetusDevelopmental Biology, 1980
- Three Conformationally Distinct Domains in the Amino-Terminal Segment of Type III Procollagen and Its Rapid Triple Helix Coil TransitionEuropean Journal of Biochemistry, 1978